Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo, Eduardo; Yactayo, Sergio; Córdova, Erika

doi:10.4269/ajtmh.13-0264

Cited by 196 publications

(182 citation statements)

References 66 publications

(87 reference statements)

Supporting

Mentioning

174

Contrasting

Unclassified

Order By: Relevance

“…We can consider this assumption conservative since a duration of protection of above 20 years has been reported for the live-attenuated yellow fever vaccine (Gotuzzo et al, 2013) and considering the waning rate and duration of protection estimated from long-term follow-up of phase III trials for preexposed people . For the first and second doses, durations of protection were estimated internally.…”

Section: Vaccinationmentioning

confidence: 99%

“…The uncertainty of these estimations was evaluated in sensibility analyses with an incidence variation of ±20%. (Coudeville et al, 2015) and other vector-borne vaccine performances (Desai et al, 2012;Gotuzzo et al, 2013) Expected duration of protection (2 nd dose) 5 years…”

Section: Epidemiology Datamentioning

confidence: 99%

“…We considered a 10-year protection after the third dose based on the duration of vaccine protection against other vector-borne diseases (Japanese encephalitis vaccine (Desai et al, 2012) and yellow fever vaccine (Gotuzzo et al, 2013)). We can consider this assumption conservative since a duration of protection of above 20 years has been reported for the live-attenuated yellow fever vaccine (Gotuzzo et al, 2013) and considering the waning rate and duration of protection estimated from long-term follow-up of phase III trials for preexposed people .…”

Section: Vaccinationmentioning

confidence: 99%

See 2 more Smart Citations

The economic impact of providing dengue vaccination in the workplace in Brazil

Durand¹,

Grailles²,

Boissière³

et al. 2017

JBES

View full text Add to dashboard Cite

Objective: To estimate the economic value of implementing a workplace dengue vaccination program from an employer perspective. Methods: The cost of a vaccination program was compared with the economic benefits in terms of reduced absenteeism and presenteeism in companies in Brazil. Input data were obtained from published literature and national databases. The time horizon was five years, including a 2-year vaccination program. Sensitivity analyses were performed to evaluate the impact of key parameters' uncertainty. Results: 846 cases were simulated among the employees over five years, accountable for 2,112 sick leave days and 7,120 sick days at work. Assuming a coverage rate of 30%, vaccination reduced the number of sick leave days and sick days at work by 17.5% over five years compared to no vaccination. Considering an employee vaccine copayment of 50%, the levels of remaining investment per dose administered for the employer in the retail sector ranged from US$ 17.99 to US$ 27.99, according to different vaccine price scenarios, and from US$ 6.10 to US$ 16.10 in the service sector. In the energy sector, vaccination was cost-saving in all price scenarios, ranging from a profit for the employer of US$ 21.14 to US$ 31.14. Results were most sensitive to the level of co-payment, overall time horizon of the analysis, dengue incidence, and employee contribution to operating income. Conclusions: Dengue contributes a significant proportion of absenteeism and presenteeism in private companies. Our analysis suggests that dengue vaccination in the workplace may be considered as a valuable investment and, in some cases, a cost-saving option for employers. RESUMOObjetivo: Estimar o valor econômico da implementação de um programa de vacinação contra a dengue no local de trabalho sob a perspectiva do empregador. Métodos: O custo de um programa de vacinação foi comparado com os benefícios econômicos em termos de redução do absenteísmo e do presenteísmo em empresas no Brasil. Os dados foram baseados na literatura publicada e em bases de dados nacionais. O horizonte temporal foi de cinco anos, incluindo um programa de vacinação de dois anos. Foram realizadas análises de sensibilidade para avaliar o impacto das incertezas de parâmetros-chave. Resultados: Oitocentos e quarenta e seis casos foram simulados entre os empregados em cinco anos, os quais foram responsáveis por 2.112 dias de licença médica e 7.120 dias com a doença no ambiente de trabalho. Assumindo uma taxa de cobertura de 30%, a vacinação reduziu o número de dias de licença médica devido à doença e os dias com a doença no ambiente de trabalho em 17,5% ao longo de cinco anos em comparação com a não realização da vacinação. Considerando um copagamento da vacinação pelos funcionários de 50%, os níveis de investimento remanescente por dose administrada para o empregador no setor varejista variaram de US$ 17,99 a US$ 27,99 de acordo com diferentes cenários de preços da vacina e de US$ 6,10 a US$ 16,10 no setor de serviços. No setor de energia, a vacinação resultou ...

show abstract

Section: Vaccinationmentioning

confidence: 99%

Section: Epidemiology Datamentioning

confidence: 99%

Section: Vaccinationmentioning

confidence: 99%

See 1 more Smart Citation

The economic impact of providing dengue vaccination in the workplace in Brazil

Durand¹,

Grailles²,

Boissière³

et al. 2017

JBES

View full text Add to dashboard Cite

show abstract

“…(Gotuzzo et al, 2013 http://www.ncbi.nlm. nih.gov/pubmed/24006295) (Gotuzzo et al, 2013) when considering the waning rate and duration of protection estimated from long-term follow-up of phase III trials for pre-exposed people Follow-up of phase II and III studies, in addition to the extensive phase IV plan, will help to refine the duration of protection. The disability weights are the one associated to "health states" and are not specific to dengue Acute dengue fever, equivalent to the health state: "infectious disease, acute episode, moderate" …”

Section: Parameters Related To Vaccinationmentioning

confidence: 99%

Cost-effectiveness of dengue vaccination in Brazil

Durand

Genovez

Araújo

2017

JBES

View full text Add to dashboard Cite

Objective: To define the economic value of a tetravalent dengue vaccine in Brazil by estimating the cost-effectiveness vaccine price threshold per dose. Methods: A dengue dynamic transmission model was used to estimate the public health impact of dengue vaccination and related economic parameters. Two vaccination strategies were assessed: routine vaccination at 9 years old plus either a catch-up campaign of 7 cohorts (10 to 16 years old; R9&10-16) or 16 cohorts (10 to 25 years old; R9&10-25). Brazilian-specific demographic, epidemiological and economic data were used. The economic impact over 10 years was estimated from the public payer and societal perspectives. All costs were expressed in BRL2016. Results: Over 10 years, the R9&10-16 and R9&10-25 vaccination strategies would prevent 9 million and 15 million dengue cases, respectively, avoiding 269,906 (95% CI: 410,097-154,653) and 434,334 (95% CI: 547,052-304,799) disability-adjusted life years. This would result in savings of up to BRL7.4 billion (US$2.1 billion) from a societal perspective with the larger vaccination program. The cost-effective vaccine price threshold per dose for the R9&10-16 and R9&10-25 strategies would be BRL187.5 (95% CI: 109-276) (US$52.1) and BRL183.6 (95% CI: 129-230) (US$51.0), respectively, from the public payer perspective, and BRL221.5 (95% CI: 129-326) (US$61.5) and BRL216.8 (95% CI: 153-271) (US$60.2), respectively, from the societal perspective. Conclusion:The high threshold of vaccine price per dose demonstrates the significant economic value of dengue vaccination in Brazil, even for a large program with 16 catch-up cohorts. RESUMOObjetivo: Definir o valor econômico da vacina tetravalente contra dengue no Brasil por meio da estimativa do limiar de preço custo-efetivo por dose. Métodos: Um modelo dinâmico de transmissão foi utilizado para estimar o impacto em saúde pública da vacinação contra dengue e os parâ-metros econômicos relacionados. A análise avaliou duas estratégias de vacinação: rotina aos 9 anos, mais campanha de vacinação com 7 coortes (10 a 16 anos; R9&10-16) ou 16 coortes (10 a 25 anos; R9&10-25). Foram utilizados dados demográficos, epidemiológicos e econômicos específicos para o Brasil. O impacto econômico foi estimado em 10 anos sob a perspectiva do pagador público e da sociedade. Todos os custos foram expressos em BRL2016. Resultados: Em 10 anos, as estratégias de vacinação R9&10-16 e R9&10-25 preveniriam 9 milhões e 15 milhões de casos de dengue, respectivamente, evitando 269,906 (95% CI: 410,097-154,653) e 434,334 (95% CI: 547,052-304,799) anos de vida ajustados por incapacidade. Isso resultaria em uma economia de até BRL7,4 bilhões (US$2,1 bilhões) sob a perspectiva da sociedade com o maior programa de vacinação. O limiar de preço custo-efetivo por dose para as estratégias R9&10-16 e R9&10-25 seria BRL187,5 (95% CI: 109-276) (US$52,1) e BRL183,6 (95% CI: 129-230) (US$51,0), respectivamente, sob a perspectiva do público pagador, e BRL221,5 (95% CI: 129-326) (US$61,5) e BRL216,8 (95% CI: 153-271) (US...

show abstract

“…Thus, in addition to vaccination campaigns in countries with reported cases, short-term intensification of control measures in vulnerable regions is necessary to avoid spread of the disease and interrupt viral circulation. However, the limited global vaccine supply in emergency situations like this has been a major obstacle to effective control of the disease 9 .…”

Section: Introduction Yellow Fever: the Diseasementioning

confidence: 99%